Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

The primary objective of this study, sponsored by Travera LLC in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats. Cohorts include patients with stage III or IV breast cancer, stage III or IV lung cancer, active AML, and relapsed multiple myeloma. This pilot study will utilize samples from patients undergoing routine biopsy of their tumor as part of their clinical care (e.g. for clinical diagnosis, staging, DNA molecular analysis). This study will involve additional material from the same procedure the patient is already undergoing.